Paper41339873
Vision rehabilitation of post-Descemet membrane endothelial keratoplasty Pseudomonas keratitis utilizing losartan ophthalmic solution and scleral contact lens: a case report.
Erdinest N and 3 others. J Med Case Rep, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Vision rehabilitation of post-Descemet membrane endothelial keratoplasty Pseudomonas keratitis utilizing losartan ophthalmic solution and scleral contact lens: a case report. Papers, record 41339873. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41339873
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Vision rehabilitation of post-Descemet membrane endothelial keratoplasty Pseudomonas keratitis utilizing losartan ophthalmic solution and scleral contact lens: a case report.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Descemet Stripping Endothelial Keratoplasty | Major topic |
| Contact Lenses | Major topic |
| Pseudomonas Infections | Major topic |
| Keratitis | Major topic |
| Losartan | Major topic |
| Postoperative Complications | Major topic |
| Humans | |
| Male | |
| Aged | |
| Visual Acuity | |
| Ophthalmic Solutions | |
| Sclera |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39133495 | Effect of Topical Losartan in the Treatment of Established Corneal Fibrosis in Rabbits. | Transl Vis Sci Technol | 2024 | https://conductscience.org/library/papers/39133495 | PubMed |
| 2 | 38570181 | Two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan. | Exp Eye Res | 2024 | https://conductscience.org/library/papers/38570181 | PubMed |
| 3 | 32190979 | Microbial keratitis and clinical outcomes following penetrating and endothelial keratoplasty. | Acta Ophthalmol | 2020 | https://conductscience.org/library/papers/32190979 | PubMed |
| 4 | 36476304 | Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits. | J Refract Surg | 2022 | https://conductscience.org/library/papers/36476304 | PubMed |
| 5 | 37179412 | False positive microbiological results in Acanthamoeba keratitis: the importance of clinico-microbiological correlation. | Eye (Lond) | 2023 | https://conductscience.org/library/papers/37179412 | PubMed |
| 6 | 39671090 | Topical Losartan for Corneal Fibrosis: A Case Series With Densitometry Analysis. | Cornea | 2026 | https://conductscience.org/library/papers/39671090 | PubMed |
| 7 | 2334323 | Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. | Arch Ophthalmol | 1990 | https://conductscience.org/library/papers/2334323 | PubMed |
| 8 | 17212987 | Infectious keratitis following keratoplasty. | Surv Ophthalmol | 2007 | https://conductscience.org/library/papers/17212987 | PubMed |
| 9 | 26917676 | Population-based assessment of vision-related quality of life in corneal disease: results from the CORE study. | Br J Ophthalmol | 2016 | https://conductscience.org/library/papers/26917676 | PubMed |
| 10 | 37712055 | A 7-year review of clinical characteristics, predisposing factors and outcomes of post-keratoplasty infectious keratitis: the Nottingham infectious keratitis study. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37712055 | PubMed |
| 11 | 22744389 | Vision-related quality of life in corneal graft recipients. | Eye (Lond) | 2012 | https://conductscience.org/library/papers/22744389 | PubMed |
| 12 | 35783647 | Host Defense Peptides at the Ocular Surface: Roles in Health and Major Diseases, and Therapeutic Potentials. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35783647 | PubMed |
| 13 | 34307431 | Post-keratoplasty Infectious Keratitis: Epidemiology, Risk Factors, Management, and Outcomes. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34307431 | PubMed |
| 14 | 36367262 | Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. | J Refract Surg | 2022 | https://conductscience.org/library/papers/36367262 | PubMed |
| 15 | 40238717 | Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity. | J Ocul Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40238717 | PubMed |
| 16 | 31686969 | Challenges in the diagnosis of microbial keratitis: A detailed review with update and general guidelines. | Saudi J Ophthalmol | 2019 | https://conductscience.org/library/papers/31686969 | PubMed |
| 17 | 16360210 | Microbial keratitis predisposing factors and morbidity. | Ophthalmology | 2006 | https://conductscience.org/library/papers/16360210 | PubMed |
| 18 | 35086233 | Post-corneal transplant Candida keratitis - Incidence and outcome. | Indian J Ophthalmol | 2022 | https://conductscience.org/library/papers/35086233 | PubMed |
| 19 | 34419639 | The epidemiology of infectious keratitis. | Ocul Surf | 2023 | https://conductscience.org/library/papers/34419639 | PubMed |
| 20 | 39441953 | Topical Losartan Dosage Response and Corneal Toxicity at Higher Concentrations. | Cornea | 2024 | https://conductscience.org/library/papers/39441953 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41339873
GET https://conductscience.org/api/papers/v1/41339873/references?page=2